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Objective: Postprostatectomy incontinence (PPI) is a major health problem that has substantial effects on
health-related quality of life. In recent years, extracorporeal magnetic innervation (ExMI) has become a
preferred treatment method for urinary incontinence. We evaluated the effects of ExMI on patients with
PPI after robotic-assisted radical prostatectomy (RARP), speciﬁcally regarding health-related quality of
life.
Materials and methods: From September to December 2014, patients with post-RARP PPI were enrolled
in the study. A 20-minute ExMI treatment session was provided twice a week for two months. Number of
voids, incontinence and urgency episodes, and mean and maximum voided volume per micturition (mL)
were recorded in a 3-day bladder diary. Quality of life was assessed using the Urogenital Distress In-
ventory (UDI-6), Incontinence Impact Questionnaire (IIQ-7), and International Prostate Symptom Score
quality-of-life questionnaire (IPSS-QoL). All assessments were conducted before and within 2 weeks after
ExMI treatment. A favorable outcome was deﬁned as an IPSS-QoL score <2 or a >2-point decrease in the
pretreatment score.
Results: Thirteen patients with a mean age of 69.3 years were enrolled. After ExMI, the number of in-
continence episodes/3 d decreased to 5.85 from 9.15 (p ¼ 0.004). The mean number of voids/d also
decreased to 9.17 from 10.45 (p ¼ 0.036). Patients' functional bladder capacity increased from 243.46 to
289.23 (p ¼ 0.007). Scores of both UDI-6 and IPSS-QoL improved from 7.15 to 5.31 (p ¼ 0.024) and 4.00 to
2.77 (p ¼ 0.007). Patients aged <70 years were more likely to have a favorable outcome [odds ratio (OR)
28.6, conﬁdence interval (CI) 1.12e731.40].
Conclusion: ExMI decreases the number of incontinence episodes, increases functional bladder capacity
and quality of life in patients with post-RARP PPI, and may be considered as an option for patients with
PPI.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Radical prostatectomy (RP) is the standard treatment for local-
ized prostate cancer. Postprostatectomy incontinence (PPI) is a
potential symptom experienced following radical prostatectomy.
Persistent PPI can be incapacitating and result in decreased qualityang Gung Memorial Hospital,
weishan Township, Taoyuan
.
ociation. Published by Elsevier Taof life (QoL).1 PPI incidence rates vary from 5% to >80%.2 Conser-
vative management techniques include pelvic-ﬂoor muscle
training with or without biofeedback, electrical stimulation,
extracorporeal magnetic innervation (ExMI), compression devices
(penile clamps), lifestyle changes, or a combination of methods. The
ability to perform robotic-assisted RP (RARP) was ﬁrst described in
2000.3 During the past decade, RARP has become widely accepted
and is now the dominant RP approach in Taiwan.4 While there are
no randomized studies comparing QoL outcomes following open
versus RARP, data from a recent meta-analysis showed a statisti-
cally signiﬁcant advantage for RARP compared to both open andiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Patient demographic characteristics (n ¼ 13).
Total
Age (y) 69.3 ± 4.8
BMI (kg/m2) 25.2 ± 3.0
PSA 17.3 ± 12.6
Prostate volume (mL) 40.5 ± 18.8
Anterior urethropexy 7 (53.8%)
Nerve sparing
Unilateral 6 (46.2%)
Bilateral 3 (23.1%)
Bladder neck preservation 6 (46.2%)
Positive surgical margin 6 (46.2%)
BMI ¼ body mass index; PSA ¼ prostate speciﬁc antigen.
Table 2
Urinary symptoms and quality of life scores at baseline and after extracorporeal
magnetic stimulation (ExMI) in patients experiencing postprostatectomy inconti-
nence (n ¼ 13).
Pre-ExMI Post-ExMI p
Incontinence episodes/3 d 9.15 ± 4.83 5.85 ± 4.53 0.004
Urgency episodes/3 d 4.77 ± 2.24 3.64 ± 2.19 0.167
Mean void times/d 10.45 ± 2.47 9.17 ± 2.27 0.036
Mean voided volume (mL) 120.97 ± 29.26 132.85 ± 36.91 0.046
Functional bladder capacity (mL) 243.46 ± 80.37 289.23 ± 87.22 0.007
UDI-6 7.15 ± 2.79 5.31 ± 2.50 0.024
IIQ-7 10.92 ± 6.08 8.69 ± 5.69 0.074
IPSS-QoL 4.0 ± 1.29 2.77 ± 1.30 0.007
Pre- and post-ExMI scores calculated using Wilcoxon signed-rank test, two-tailed p
values.
IIQ-7 ¼ Incontinence Impact Questionnaire; IPSS-QoL ¼ International Prostate
Symptom Score quality-of-life questionnaire; UDI-6 ¼ Urogenital Distress
Inventory.
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recovery.5
Electrical stimulation was ﬁrst used to treat urinary inconti-
nence in 19636 and is reportedly effective at treatments associated
with female stress and urge incontinence.7,8 Electrical stimulation
performed better than control interventions for PPI patients in
terms of less incontinence, continence reacquisition, and improved
QoL during a 6-month period.9,10 Unlike electrical stimulation,
ExMI uses a magnetic chair to stimulate contraction of pelvic-ﬂoor
muscles and sacral-nerve roots. ExMI is a relatively painless,
noninvasive, and convenient form of electrical therapy that is more
acceptable to patients suffering from urinary incontinence.11 Data
from individual trials suggest that ExMI alone or in combination
with other treatments may be beneﬁcial for PPI patients.
Here, we investigate the effect of ExMI on PPI patients, specif-
ically regarding health-related QoL.
2. Materials and methods
From September to December 2014, patients with post-RARP
urinary incontinence were enrolled in the study. The medical his-
tory, prostate cancer parameters, and surgical techniques were
recorded. All surgeries were performed by the same surgeon (CT
Wu). A 3-day bladder diary was completed at baseline and within 2
weeks of completing ExMI therapy to evaluate voiding patterns and
any possible changes.
The BioCon-2000W system (Mcube Technology, Seoul, South
Korea) was used for ExMI. During treatment, the patients were
instructed to sit on the chair fully clothed in order to position the
perineum at the center of the coil and were informed that they
would feel anal-sphincter contraction during stimulation. Stimu-
lation was provided by an electromagnetic generator underneath
the seat controlled by an external unit. Treatment sessions were 20
minutes, twice weekly, for 2 months. Pulse-ﬁeld frequency was
10 Hz applied intermittently for 10minutes, followed by a 1-minute
rest period, then a second treatment at 50 Hz applied intermit-
tently for 10 minutes.
The primary end point represented changes in the number of
urinary incontinence episodes recorded in the 3-day bladder diary.
Secondary end points represented changes in the mean number of
voids/24 h and urgency episodes, mean voided volume/micturition
(mL), and maximum voided volume/mL (functional bladder ca-
pacity, mL) recorded in the 3-day bladder diary. Incontinence
symptoms and QoL were evaluated by self-administered validated
versions of the Urogenital Distress Inventory-short form (UDI-6),
Incontinence Impact Questionnaire-short form (IIQ-7), and Inter-
national Prostate Symptom Score-QoL questionnaire (IPSS-QoL),
Chinese-language version.12 Favorable outcomes were deﬁned as
an IPSS-QoL score <2 indicating that participants were mostly
satisﬁed or pleased post-ExMI treatment or a >2-point decrease in
the pretreatment score.
Mean ± standard deviation was calculated for each of the pri-
mary and secondary outcome variables. The Wilcoxon signed-rank
test was used for pre- and post-treatment comparisons with a
signiﬁcance level of 0.05 (two-tailed). All statistical analyses were
carried out using SPSS version 13 (SPSS, Inc., Chicago, IL, USA).
3. Results
A total of 13 patients with post-RARP urinary incontinence were
enrolled in the study. Demographics and clinical characteristics are
shown in Table 1. Nine patients within 1 year after RARP, and four
patients experiencing persistent incontinence 4.0e7.5 years after
RARPwere enrolled. Most patients suffered fromvarying degrees of
urinary incontinence, except for one experiencing pure-urgeincontinence and another experiencing pure-stress incontinence.
All patients reached 100% treatment intensity and completed the 2-
month treatment session with no reported adverse symptoms.
Following 2 months of ExMI therapy, the mean number of in-
continence episodes recorded in the 3-day bladder diary decreased
by 36% (9.15 ± 4.83 to 5.85 ± 4.53, p ¼ 0.004; Table 2, Figure 1). The
patients' mean functional bladder capacity increased by 19%
(243.46 ± 87.22 to 289.23 ± 8 7.22, p ¼ 0.007; Table 2, Figure 2),
however, there was only a marginal increase in their mean voided
volume (120.97 ± 29.26 to 132.85 ± 36.91, p ¼ 0.046; Table 2) and a
marginal decrease in the mean voiding frequency per day (10.45 ±
29.26 to 9.17 ± 2.27, p ¼ 0.036) recorded in the 3-day bladder diary.
UDI-6 scores were signiﬁcantly lower following ExMI
(7.15 ± 2.79 to 5.31 ± 2.50, p¼ 0.024; Table 2). When each of the six
questions was compared separately, scores on the fourth question
showed the most signiﬁcant decrease (1.69 to 1.07, p ¼ 0.02).
Notably, the mean score for the ﬁfth question, regarding difﬁculty
in emptying the bladder, was 0.15 before ExMI and decreased to
zero following ExMI (p ¼ 0.165). The mean score for the sixth
question, regarding pain and discomfort, increased from 0.46 to
0.54 following ExMI, however, the change was not statistically
signiﬁcant (p ¼ 0.337).
IIQ-7 scores decreased from 10.92 ± 6.08 to 8.69 ± 5.69
following ExMI (p ¼ 0.074), however, the change was not statisti-
cally signiﬁcant. Whenwe examined each of the seven questions, a
trend of decreasing scores following treatment was observed for all
questions, however, none of the changes were statistically signiﬁ-
cant. The mean IPSS-QoL score signiﬁcantly decreased from
4.0 ± 1.29 to 2.77 ± 1.31 (p ¼ 0.007).
Eight of the 13 patients had a favorable outcome following ExMI.
Compared to older patients, those <70 years of age were signiﬁ-
cantly more likely to have a favorable outcome [Odds ratio (OR)
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Figure 1. Number of incontinence episodes recorded over 3 days by 13 patients
experiencing urinary incontinence following robotic-assisted radical prostatectomy
and before and after 2 months of ExMI therapy. ExMI ¼ Extracorporeal magnetic
innervation.
Table 3
Association between patient outcome after extracorporeal magnetic innervation
(ExMI) and selected risk factors (n ¼ 13).
Patient outcome OR (95% CI)
Unfavorable (n ¼ 5) Favorablea (n ¼ 8)
Age (y)
>70 5 2 1
70 0 6 28.6 (1.12e731.4)
BMI
24 1 4 1
>24 4 4 0.25 (0.02e3.34)
PSA
20 3 5 1
>20 2 3 0.9 (0.09e8.90)
Prostate volume (mL)
40 3 5 1
>40 2 3 0.9 (0.09e8.90)
Anterior urethropexy
No 3 3 1
Yes 2 5 2.5 (0.25e24.72)
Nerve sparing
No 2 2 1
Yes 3 6 2.0 (0.18e22.06)
Bladder neck preservation
No 2 4 1
Yes 3 4 0.66 (0.07e6.41)
Pathological T stage
T2 3 5 1
T3 2 3 0.9 (0.09e8.90)
Positive surgical margin
No 3 4 1
Yes 2 4 1.5 (0.16e14.42)
Early ExMIb
No 3 1 1
Yes 2 7 10.5 (0.67e165.11)
BMI ¼ body mass index; CI ¼ conﬁdence interval; OR ¼ odds ratio; PSA ¼ prostate
P.-C. Chang et al. / Urological Science 26 (2015) 250e25325228.6, 95% conﬁdence interval (CI) 1.12e731.4; Table 3]. Patients
receiving ExMI therapy within 1 year following RARP were also
more likely to have a favorable outcome (OR 10.5, 95% CI
0.67e165.11). Patients' body mass index, serum level of prostate
speciﬁc antigen, prostate volume, and pathological T stage did not
differ between those having a favorable or unfavorable outcome.
Surgical techniques, including anterior urethropexy, nerve sparing,
bladder neck preservation, and positive surgical margin did not
affect patient outcome following ExMI therapy.speciﬁc antigen.
a Post-treatment International Prostate Symptom Score-quality-of-life measure-
ment <2 or a >2-point decrease in the pretreatment score.
b Patients receiving ExMI within 1 year following radical prostatectomy.4. Discussion
While incontinence and impotence are the two major draw-
backs associated with RARP, incontinence appears to be the most
problematic, despite its lower incidence compared to that of
impotence.13 Reported PPI prevalence varies from 3% to 74%,
depending on the deﬁnition, evaluation timing, surgical technique,
preoperative condition of the patient, and the individual perform-
ing the evaluation (physician or patient).11,14
PPI etiology is complex. Chao and Mayo15 showed urody-
namically that 57% of patients had pure sphincteric insufﬁciency0
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Figure 2. Functional bladder capacity of 13 patients experiencing urinary incontinence
following robotic-assisted radical prostatectomy and before and after 2 months of
ExMI therapy. ExMI ¼ Extracorporeal magnetic innervation.and 39% had sphincteric weakness combined with detrusor
dysfunction. Leach et al16 reported that 40% of patients had pure
sphincteric insufﬁciency, while 56% had detrusor instability with
or without poor bladder compliance. In a clinical scenario, pa-
tients experience incontinence immediately following RARP. We
found that they tended to urinate before bladder fullness or urge
sensation in order to prevent subsequent leakage. Additionally,
they tended to empty their bladder in advance of any activity.
Therefore, as PPI improves, voided volume and functional bladder
capacity gradually increases and void frequency decreases. We
found that patients' functional bladder capacity signiﬁcantly
improved following ExMI therapy, emphasizing the role of
detrusor dysfunction in PPI.
PPI patients have both detrusor dysfunction and sphincter
insufﬁciency, causing them to suffer simultaneously from a
mixture of urge and stress incontinence. Studies of PPI patient
voiding patterns indicate that stress incontinence is present in all
patients, while concomitant urgency/urge incontinence is pre-
sent in 48%.17 Results from both animal studies and healthy
volunteers indicate that ExMI increases maximal urethral closure
pressure and inhibits detrusor overactivity. Several randomized
comparative studies were carried out to investigate the urody-
namic and clinical effects of magnetic stimulation on patients
displaying varying etiologies of urinary incontinence. In those
with urinary incontinence due to detrusor overactivity, Yama-
nishi et al8 found that the increase in volume at ﬁrst desire to
void and the maximum cystometric capacity were signiﬁcantly
greater in the magnetic stimulation group than that observed in
P.-C. Chang et al. / Urological Science 26 (2015) 250e253 253the electrical stimulation group (105.5 ± 130.4% vs. 16.3 ± 33.9%).
In another study involving women with mixed incontinence,
ExMI successfully decreased patients' voiding frequency, nocturia
and pad use, and improved their urodynamic parameters,
including ﬁrst sensation and maximum cystometric capacity.18
In our study, all incontinence episodes were recorded in the 3-
day bladder diary, however, we could not differentiate stress from
urge incontinence episodes. The second and third UDI-6 questions
were inquiries regarding urge and stress incontinence, respectively.
Our patients' average scores on the second and third questions
showed similar improvements following ExMI therapy (1.69 to 1.23
and 1.54 to 1.15, p ¼ 0.213 and p ¼ 0.209, respectively). To better
elucidate the effect of ExMI on the stress and/or urge components
of PPI patient incontinence, objective measurements, such as the
pad test or a urodynamic study, and a more detailed questionnaire
(Expanded Prostate Cancer Index Composite Incontinence subscale
or International Consultation on Incontinence Questionnaire) must
be included in future studies.
Older patients not only have a higher PPI risk, but also need
more recovery time.19,20 Besides age, other RP-associated PPI risk
factors include pre-existing abnormalities of detrusor contractility,
previous transurethral resection of the prostate, preoperative
radiotherapy, and surgeon experience.11 In our study, patients >70
years of age tended to have an unfavorable response to ExMI
therapy. This may be due to evidence in older men of rhabdos-
phincter atrophy and neural degeneration or possibly the natural
course of aging.11,21 Younger PPI patients may beneﬁt themost from
ExMI, however, given its minimal side effects, we suggest that ExMI
should also be offered to older patients.
Many patients complain of incontinence immediately
following urethral catheter removal, however, PPI symptoms
gradually improve over time. Most investigators agree that post-
operative continence rates plateau at 2 years, from 80.6% at 3
months to 95.2% at 12 months and 98.5% at 24 months.21 No study
has been speciﬁcally designed to evaluate efﬁcacy of conservative
treatment of patients suffering from PPI for >2 years. In our study,
we found that patients receiving ExMI therapy within 1 year
following RARP were more likely to have a favorable outcome. It is
possible that some patients were in their natural course of post-
operative recovery and ExMI provided minimal beneﬁt. However,
patients who had undergone RARP years ago (range, 4.0e7.5) also
beneﬁted from ExMI. Therefore, we suggest that ExMI should be
considered as a treatment option for all patients experiencing PPI,
regardless of their age or the time that has elapsed since radical
prostatectomy.
There are several limitations in the present study. First, only the
short-term effect of ExMI was evaluated. Compared with control
groups, ExMI offers earlier continence for prostatectomy patients.22
Our ﬁndings provide further evidence of the immediate beneﬁcial
effects of ExMI. While studies focusing on the long-term effects of
ExMI are not currently available, short-term improvement in
continence symptoms and QoLmaywarrant ExMI in some patients.
Further collection of follow-up data should be undertaken to pro-
vide insight into long-term efﬁcacy or treatment durability. Second,
urodynamic evaluation was not performed on all patients. Urody-
namic parameters collected before and after ExMIwill providemore
information on PPI pathophysiology and potential therapeutic
beneﬁts.
In conclusion, patients with post-RARP PPI beneﬁt from ExMI,
and treatment with ExMI may be considered as an option for all
patients experiencing PPI.Conﬂicts of interest
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